Results from a post hoc subgroup analysis of the SURMOUNT-1 study (NCT04184622), published this year [87] , demonstrated that among 32 pathogenic MC4R variant carriers (1.4% of the study population) with a median age of 41.06 years and a BMI 40 kg/m 2 , treatment with tirzepatide for 72 weeks resulted in an 18.3% reduction in body weight from baseline
Toffanello ED, Inelmen EM, Minicuci N, Campigotto F, Sergi G, Coin A, et al
Without insurance, branded semaglutide may be costly, but with competent insurance support and prior authorization from Klinic, many patients find affordable solutions
Potential clinical implications and challenges with the new obesity pharmacotherapies A new era in obesity management Tirzepatide has received FDA and EMA approval for chronic weight management and results in 20% mean WL in people without T2D
Some users self-report increased hunger
As a result, cravings increase , satiety drops and your ability to manage weight becomes harder , even going into the next day
